Screener
CRISPR Therapeutics CRSP Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
| Line item | As of / March 31, 2026 | As of / December 31, 2025 |
|---|---|---|
| Property and equipment, net | 112,175 | 115,851 |
| Restricted cash | 7,629 | 7,629 |
| Operating lease assets | 128,671 | 131,724 |
| Other non-current assets | 28,983 | 24,368 |
| Total assets | $2,725,820 | $2,265,243 |
| Liabilities and shareholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $13,647 | $11,138 |
Item 1. Financial Statements
FAQ
- What is CRISPR Therapeutics's deferred tax assets and other non-current assets?
- CRISPR Therapeutics (CRSP) reported deferred tax assets and other non-current assets of $28.98M in Q1 2026.
- How has CRISPR Therapeutics's deferred tax assets and other non-current assets changed year-over-year?
- CRISPR Therapeutics's deferred tax assets and other non-current assets increased by 39.5% year-over-year, from $20.78M to $28.98M.
- What is the long-term trend for CRISPR Therapeutics's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), CRISPR Therapeutics's deferred tax assets and other non-current assets has grown at a 79.9% compound annual growth rate (CAGR), from $1.29M to $24.37M.
Ask your AI about CRISPR Therapeutics's deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude